With over 25 years‘ experience, HOF Sonderanlagenbau GmbH is the leading specialist in the manufacture of individual freeze drying systems, loading and unloading systems, as well as freeze-thaw units for the pharmaceutical and biotechnological industry. At our company location in Lohra, near Marburg, Germany, highly motivated and specially qualified employees work on the company‘s own production floor of some 12,500m2. A flexible service team keeps close contact with our customers, both nationally and internationally, providing support for the users of HOF systems.


In the pharmaceutical and biotechnological environment, quality and reliability are the decisive parameters in determining whether a company will be successful or not. This is guaranteed by using HOF‘s customized systems, but also because the company‘s systems technology is developed with an eye on the requirements of the future. The company, a specialist in individual solutions since its founding, distinguishes itself by offering only the highest quality in all stages: from the idea to the fully developed plan, all the way to the scrupulous manufacture of the system, which is customized and convincingly reliable. HOF systems are always a good investment for the future.


You are welcome to watch our Corporate Video on our homepage.

TECHNOLOGY

At HOF, it isn‘t technology which determines the product - it‘s the product properties which determine the technology. We rely on the most modern technological advances in our facilities and systems so we can provide our customers with excellent results, as reliably and as efficiently as possible. These technological advances include, for example, recipe-controlled automatic shelf adjustment, the use of PAT sensor technology, comparative pressure measurement and our controlled nucleation method ‘SYNCHROFREEZE’.

INNOVATION

Future-proof, high-performance and practice-oriented – these are the decisive parameters by which HOF systems measure themselves. The company is well-known for creative products which are developed to satisfy customer requirements using the latest technologies. Innovative solutions and individual designs help our customers to successfully achieve their goals.

CONSULTING

A team of experienced employees will give you individual advice from the very beginning of a project and accompany you as a partner through all processes up to the point when the system is working successfully. You can rely on employees who were trained especially for this task by HOF.

MANUFACTURE

Our dominant position compels us to be consistently excellent in our performance, high quality and farsightedness when developing trendsetting technologies. All HOF systems are manufactured and inspected fully by our employees at our production sites. This way we are able to guarantee the highest standards of quality. 

QUALITY

With every HOF system, our goal is only achieved when the result fully meets your expectations, not to 99%, but to the full 100%. For HOF, quality is the highest measure of things, and that applies to all areas, from the concept all the way to service – you can count on that!

EXPERTISE

The knowledge, ability and experience of our employees form the basis of our work. Decisive investments in our future are comprehensive training and a continual transfer of knowledge, which ensures that our highly qualified employees have wide-ranging expertise and can identify themselves with the products of HOF. This large set of skills gives you the security of knowing you‘ve made the right choice, which you can rely on during everyday production. 

Go to article: Home | CRISPR gene therapies cut through in 2023Go to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: TripletreeGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: HOF SonderanlagenbauGo to article: Owen Mumford Company InsightGo to article: Owen Mumford AidaptusGo to article: CommentGo to article: High hopes for mRNA anti-cancer vaccines with early successesGo to article: Cell therapies might revolutionise treatment for multiple sclerosis patientsGo to article: Downturn for top biopharma companies as Covid-19 vaccine demand falls in Q3Go to article: Inflation threatens supply of life-saving generics to EuropeGo to article: Data is the key to a safer and more controlled pharmaceutical cold-chainGo to article: Molnar-Institute Company Insight Go to article: Molnar-InstituteGo to article: In DepthGo to article: CRISPR gene therapies: Is 2023 a milestone year in the making?Go to article: Tracking the ups and downs of pharma dealsGo to article: Regulation starts to catch up with AI in pharmaGo to article: Next on trial diversity: Embracing participants with cognitive impairmentGo to article: Digital twins: The next frontier to ease clinical trial conductGo to article: CMO Moves: Regulatory catalysts for therapy manufacturing -JanuaryGo to article: EventsGo to article: Next issue